{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:39:43Z","timestamp":1791250783908,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metastatic bone disease develops as a result of the many interactions between tumor cells and bone cells. This leads to disruption of normal bone metabolism, with the increased osteoclast activity seen in most, if not all, tumor types providing a rational target for treatment. The clinical course of metastatic bone disease in multiple myeloma, breast and prostate cancers is relatively long, with patients experiencing sequential skeletal complications over a period of several years. These include bone pain, fractures, hypercalcemia, and spinal cord compression, all of which may profoundly impair a patient's quality of life.<\/jats:p><jats:p>External beam radiotherapy and systemic endocrine and cytotoxic treatments are the mainstay of treatment in advanced cancers. However, it is now clear that the bisphosphonates provide an additional treatment strategy, which reduces both the symptoms and complications of bone involvement. Additionally, new specific molecules such as osteoprotogerin have been developed that are based on our improved understanding of the cellular signaling mechanisms involved in cancer-induced bone disease. These potent molecules are now entering clinical trials.<\/jats:p><jats:p>Ongoing research is aimed at trying to define the optimum route, dose, schedule and type of bisphosphonate in metastatic bone disease and its use in the prevention and treatment of osteoporosis in cancer patients. In vitro suggestions of direct anticancer activity and some promising clinical data in early breast cancer have resulted in considerable interest in the possible adjuvant use of bisphosphonates to inhibit the development of bone metastases.<\/jats:p>","DOI":"10.1634\/theoncologist.5-6-463","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"463-470","source":"Crossref","is-referenced-by-count":126,"title":["Management of Bone Metastases"],"prefix":"10.1093","volume":"5","author":[{"given":"Robert E.","family":"Coleman","sequence":"first","affiliation":[{"name":"Yorkshire Cancer Research Department of Clinical Oncology, Cancer Research Center, Weston Park Hospital, Sheffield, England"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2000,12,1]]},"reference":[{"key":"2021122210022745800_R1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122210022745800_R2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"issue":"suppl 8","key":"2021122210022745800_R3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1","article-title":"Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals","volume":"80","author":"Janjan","year":"1997","journal-title":"Cancer"},{"key":"2021122210022745800_R4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur J Cancer"},{"issue":"suppl 2","key":"2021122210022745800_R5","first-page":"44","article-title":"Clinical experience with strontium-89 in prostatic and breast cancer patients","volume":"20","author":"Robinson","year":"1993","journal-title":"Semin Oncol"},{"key":"2021122210022745800_R6","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0959-8049(97)00155-X","article-title":"A dose-controlled study of 153Sm-Ethylenedia minetetramethylenephosphate (EDTMP) in the treatment of patients with painful bone metastases","volume":"33","author":"Resche","year":"1997","journal-title":"Eur J Cancer"},{"key":"2021122210022745800_R7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00003086-198912000-00027","article-title":"Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathological fracture","volume":"249","author":"Mirels","year":"1989","journal-title":"Clin Orthop"},{"issue":"suppl 12","key":"2021122210022745800_R8","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W","article-title":"Complications of bone metastases\u2014surgical management","volume":"88","author":"Healey","year":"2000","journal-title":"Cancer"},{"issue":"suppl 8","key":"2021122210022745800_R9","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"2021122210022745800_R10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/ctrv.1999.0133","article-title":"Use of bisphosphonates for the treatment of bone metastasis in experimental animal models","volume":"25","author":"Yoneda","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"2021122210022745800_R11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/ctrv.1999.0143","article-title":"Tumour progression and angiogenesis in bone metastases from breast cancer: new approaches to an old problem","volume":"26","author":"Pluijm","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"2021122210022745800_R12","first-page":"147","article-title":"Pamidronate disodium in the treatment and management of hypercalcaemia","volume":"9","author":"Coleman","year":"1998","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"2021122210022745800_R13","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122210022745800_R14","first-page":"575a","article-title":"Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone","volume":"18","author":"Body","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"2021122210022745800_R15","first-page":"586a","article-title":"Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases","volume":"88","author":"Berenson","year":"1998","journal-title":"Blood"},{"key":"2021122210022745800_R16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1008238422151","article-title":"Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease","volume":"8","author":"Vinholes","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122210022745800_R17","first-page":"137","volume-title":"Cancer and the Skeleton","author":"Coleman","year":"2000"},{"key":"2021122210022745800_R18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(96)90020-1","article-title":"Use of bisphosphonates in cancer patients","volume":"22","author":"Body","year":"1996","journal-title":"Cancer Treat Rev"},{"key":"2021122210022745800_R19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122210022745800_R20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"2021122210022745800_R21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122210022745800_R22","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre randomised controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122210022745800_R23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/02841869609083974","article-title":"Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial","volume":"35","author":"Hultborn","year":"1996","journal-title":"Acta Oncol"},{"key":"2021122210022745800_R24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122210022745800_R25","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"Eur J Cancer"},{"key":"2021122210022745800_R26","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases: long-term results of two randomised, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"2021122210022745800_R27","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.1999.14.9.1557","article-title":"A dose-finding study of zoledronate in hypercalcaemic cancer patients","volume":"14","author":"Body","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2021122210022745800_R28","first-page":"604a","article-title":"Zoledronic acid is superior to pamidronate in the treatment of tumor-induced hypercalcamia: a pooled analysis","volume":"19","author":"Major","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122210022745800_R29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","article-title":"Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease","volume":"10","author":"Coleman","year":"1999","journal-title":"Ann Oncol"},{"key":"2021122210022745800_R30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss which is reduced by clodronate: a randomised study in premenopausal patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122210022745800_R31","first-page":"468a","article-title":"Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer","volume":"17","author":"Powles","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122210022745800_R32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122210022745800_R33","first-page":"128a","article-title":"No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients","volume":"18","author":"Saarto","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122210022745800_R34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"2021122210022745800_R35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/74999","article-title":"Osteoprotogerin blocks bone cancer-induced skeletal destruction. Skeletal pain and pain-related neurochemical re-organisation of the spinal cord","volume":"6","author":"Honore","year":"2000","journal-title":"Nat Med"},{"key":"2021122210022745800_R36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment","volume":"ii","author":"Holten-Verzantvoort","year":"1987","journal-title":"Lancet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.5-6-463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.5-6-463","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/6\/463\/41837445\/oncolo_5_6_463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/6\/463\/41837445\/oncolo_5_6_463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T06:56:13Z","timestamp":1705215373000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/5\/6\/463\/6385861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12,1]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2000,12,1]]},"published-print":{"date-parts":[[2000,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.5-6-463","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,12,1]]},"published":{"date-parts":[[2000,12,1]]}}}